Paper42979487PubMed
Key Players and Pathways of Mast Cell Activation in Urticaria.
Jahn C and 4 others. J Inflamm Res, 2026.
Cite this record
ConductScience Library. Key Players and Pathways of Mast Cell Activation in Urticaria. Papers, record 42979487. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42979487
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Key Players and Pathways of Mast Cell Activation in Urticaria.
- Journal
- J Inflamm Res
- Year
- 2026
- Publication types
- Journal Article, Review
- Revised in PubMed
- 2026-11-05
Source PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References179
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 8675625 | Serum IgG autoantibodies directed against the alpha chain of Fc epsilon RI: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients? | J Clin Invest | 1995 | https://conductscience.org/library/papers/8675625 | PubMed |
| 2 | 24954276 | Expression of Mas-related gene X2 on mast cells is upregulated in the skin of patients with severe chronic urticaria. | J Allergy Clin Immunol | 2014 | https://conductscience.org/library/papers/24954276 | PubMed |
| 3 | 38533368 | Levels of serum inflammatory cytokines and their correlations with disease severity in patients with chronic spontaneous urticaria. | Postepy Dermatol Alergol | 2024 | https://conductscience.org/library/papers/38533368 | PubMed |
| 4 | 34808483 | Thrombin induces pro-inflammatory and anti-inflammatory cytokines secretion from human mast cell line (HMC-1) via protease-activated receptors. | Mol Immunol | 2022 | https://conductscience.org/library/papers/34808483 | PubMed |
| 5 | 40782271 | Autoallergy and what the Allergist Needs to know. | Curr Allergy Asthma Rep | 2025 | https://conductscience.org/library/papers/40782271 | PubMed |
| 6 | 37506162 | The correlation between Th17/Treg immune dysregulation and the disease severity in chronic spontaneous urticaria patients. | Immun Inflamm Dis | 2023 | https://conductscience.org/library/papers/37506162 | PubMed |
| 7 | 15010370 | NTAL phosphorylation is a pivotal link between the signaling cascades leading to human mast cell degranulation following Kit activation and Fc epsilon RI aggregation. | Blood | 2004 | https://conductscience.org/library/papers/15010370 | PubMed |
| 8 | 10447728 | Evaluation of C3a receptor expression on human leucocytes by the use of novel monoclonal antibodies. | Immunology | 1999 | https://conductscience.org/library/papers/10447728 | PubMed |
| 9 | 18802362 | Expression of tissue factor by eosinophils in patients with chronic urticaria. | Int Arch Allergy Immunol | 2009 | https://conductscience.org/library/papers/18802362 | PubMed |
| 10 | 28389391 | Omalizumab is effective in symptomatic dermographism-results of a randomized placebo-controlled trial. | J Allergy Clin Immunol | 2017 | https://conductscience.org/library/papers/28389391 | PubMed |
| 11 | 41914312 | Immunological Basis of Chronic Spontaneous Urticaria: Immunoglobulin E and Beyond. | Yonsei Med J | 2026 | https://conductscience.org/library/papers/41914312 | PubMed |
| 12 | 28303277 | Basophil FcεRI Expression in Chronic Spontaneous Urticaria: A Potential Immunological Predictor of Response to Omalizumab Therapy. | Acta Derm Venereol | 2017 | https://conductscience.org/library/papers/28303277 | PubMed |
| 13 | 20613776 | Cholinergic urticaria: studies on the muscarinic cholinergic receptor M3 in anhidrotic and hypohidrotic skin. | J Invest Dermatol | 2010 | https://conductscience.org/library/papers/20613776 | PubMed |
| 14 | 30651343 | Angiogenic Host Defense Peptide AG-30/5C and Bradykinin B2 Receptor Antagonist Icatibant Are G Protein Biased Agonists for MRGPRX2 in Mast Cells. | J Immunol | 2019 | https://conductscience.org/library/papers/30651343 | PubMed |
| 15 | 20203527 | Heparin and tranexamic Acid therapy may be effective in treatment-resistant chronic urticaria with elevated d-dimer: a pilot study. | Int Arch Allergy Immunol | 2010 | https://conductscience.org/library/papers/20203527 | PubMed |
| 16 | 41967676 | Clinical Evolution of Acute Urticaria and Association With IgE Autoantibodies. | J Allergy Clin Immunol Pract | 2026 | https://conductscience.org/library/papers/41967676 | PubMed |
| 17 | 16785568 | Fc gamma RIIa, not Fc gamma RIIb, is constitutively and functionally expressed on skin-derived human mast cells. | J Immunol | 2006 | https://conductscience.org/library/papers/16785568 | PubMed |
| 18 | 32888945 | Coagulation factors induce human skin mast cell and basophil degranulation via activation of complement 5 and the C5a receptor. | J Allergy Clin Immunol | 2021 | https://conductscience.org/library/papers/32888945 | PubMed |
| 19 | 17827066 | Hyperexpression of FcgammaRI and Toll-like receptor 4 in the intestinal mast cells of Crohn's disease patients. | Clin Immunol | 2007 | https://conductscience.org/library/papers/17827066 | PubMed |
| 20 | 41005705 | Efficacy, Safety, and Quality-of-Life Outcomes of Remibrutinib in Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis. | J Allergy Clin Immunol Pract | 2025 | https://conductscience.org/library/papers/41005705 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42979487
GET https://conductscience.org/api/papers/v1/42979487/references?page=2